Celldex Therapeutics, Inc vs. Immucell Corp
Celldex Therapeutics, Inc and Immucell Corp are evenly matched on the factors we track — the better pick depends on what you're optimizing for.
Size & Scale
| CLDX | ICCC | |
|---|---|---|
| Market Cap | $3.17 billion | $91.37 million |
| Revenue (TTM) | — | $30.68 million |
| Net Income (TTM) | — | $787,373 |
CLDX leads on 1 of 1 size & scale factors.
Valuation
| CLDX | ICCC | |
|---|---|---|
| P/E Ratio | — | 143.71 |
| Price / Book | — | 2.91 |
| Price / Sales | — | 2.98 |
CLDX and ICCC split the valuation factors evenly.
Profitability
| CLDX | ICCC | |
|---|---|---|
| Net Margin | — | 2.57% |
| Return on Equity | — | 2.51% |
CLDX and ICCC split the profitability factors evenly.
Risk & Sentiment
| CLDX | ICCC | |
|---|---|---|
| Short Interest | 9.28% | 0.20% |
ICCC leads on 1 of 1 risk & sentiment factors.
Dig deeper: CLDX overview, CLDX financials, ICCC overview, ICCC financials.
Comparisons use delayed, cached fundamental data and cover only the factors shown. For informational purposes only — not investment advice.